Acadia listing price is US$575,000 to US$595,000. Will Royalties be calculated on US$575,000 or US$375,000?
I suspect the royalties will be calculated on the sale price less some selling cost as “net sales” which should be higher than net realised cost of US$375,000, imo.
Acadia's rare-disease drug to cost $575,000 to $595,000
Acadia Pharmaceuticals Inc. ACAD said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-117
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.31 |
Change
0.770(6.14%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $12.96 | $14.00 | $12.91 | $19.76M | 1.453M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $13.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.33 | 3716 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |